Translating Proteomics Episode 14: Expanding the Drug Development Toolkit with Proteomics

Chapters

00:00 – 01:06 – Introduction
01:06 – 06:51 – Proteomics in pre-clinical studies
06:51 – 11:40 – The importance of choosing the right model for preclinical work
11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials
17:10 – 19:29 – Proteomics tools in patient selection
19:29 – 24:33 – Useful information that we get from proteomics that we can’t get from genomics or transcriptomics
24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy
28:14 – 29:19 – Understanding why clinical trials fail
29:19 – End – Outro

Resources

• The National Cancer Institute’s webpage covering how clinical trials work
• Preprint on the miBrain model – An example of a new in vitro brain model
• Wasko et al., 2024 – Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
• Geary et al., 2021 – Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials
• The NCI-MATCH trail: Lessons for precision oncology – Report on a large-scale trial using genomic biomarkers to match cancer patients to treatments
• Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer – Study using proteomics to understand mechanisms of resistance to a cancer drug

Find this episode on Apple Podcasts, Spotify, or YouTube.

Browse all episodes of Translating Proteomics.